Reducing the dose of gonadotrophin-releasing hormone agonist on starting ovarian stimulation: effect on ovarian response and in-vitro fertilization outcome.

Elgendy M, Afnan M, Holder R, Lashen H, Afifi Y, Lenton W, Sharif K

Human reproduction (Oxford, England)1 Sept 1998Cited by 12 (Europe PMC)

PMID9806253DOI10.1093/humrep/13.9.2382PepBankPUB-09806253

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

01HumanRandomized controlled trialEfficacy outcome
In IVF patients, reduced-dose nafarelin produced significantly higher LH than continued higher-dose nafarelin on the HCG administration day.
In plain wordsLH was higher with reduced-dose than continued higher-dose nafarelin on the HCG administration day.
Peptide
Nafarelin
Outcome
IncreaseLH on HCG administration day
Study
n = 64
Comparator
Nafarelin 200 microg three times daily throughout stimulation
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
200 microg three times daily, reduced to 200 microg twice daily at ovarian stimulation · intranasalAs given in this study (human).
Source sentences
Summary
LH and oestradiol were found to be significantly higher in the lower Synarel dose group.
3 context sentences(design, population, supporting numbers)
Summary · context
Blood samples were taken on the day of HCG administration to measure luteinizing hormone (LH), oestradiol, and progesterone.
Summary · context
A total of 64 normally ovulating patients entering an IVF programme were randomized to receive GnRHa (nafarelin acetate/Synarel) as an intranasal spray commencing in the midluteal phase, either at a dosage of 200 microg three times daily until the day of human chorionic gonadotrophin (HCG) administr…
Summary · context
All patients received three ampoules of Metrodin HP per day.
Report a problemFND-0980625301
02HumanRandomized controlled trialEfficacy outcome
In IVF patients, reduced-dose nafarelin produced significantly higher oestradiol than continued higher-dose nafarelin on the HCG administration day.
In plain wordsOestradiol was higher with reduced-dose than continued higher-dose nafarelin on the HCG administration day.
Peptide
Nafarelin
Outcome
IncreaseOestradiol on HCG administration day
Study
n = 64
Comparator
Nafarelin 200 microg three times daily throughout stimulation
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
200 microg three times daily, reduced to 200 microg twice daily at ovarian stimulation · intranasalAs given in this study (human).
Source sentences
Summary
LH and oestradiol were found to be significantly higher in the lower Synarel dose group.
3 context sentences(design, population, supporting numbers)
Summary · context
Blood samples were taken on the day of HCG administration to measure luteinizing hormone (LH), oestradiol, and progesterone.
Summary · context
A total of 64 normally ovulating patients entering an IVF programme were randomized to receive GnRHa (nafarelin acetate/Synarel) as an intranasal spray commencing in the midluteal phase, either at a dosage of 200 microg three times daily until the day of human chorionic gonadotrophin (HCG) administr…
Summary · context
All patients received three ampoules of Metrodin HP per day.
Report a problemFND-0980625302
03HumanRandomized controlled trialEfficacy outcome
In IVF patients, reduced-dose nafarelin yielded significantly more oocytes than continued higher-dose nafarelin.
In plain wordsReduced-dose nafarelin yielded more oocytes than continued higher-dose nafarelin.
Peptide
Nafarelin
Outcome
IncreaseOocytes recovered
Study
n = 64
Comparator
Nafarelin 200 microg three times daily throughout stimulation
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
200 microg three times daily, reduced to 200 microg twice daily at ovarian stimulation · intranasalAs given in this study (human).
Source sentences
Summary
Our results show that reducing the GnRHa dose during ovarian stimulation in IVF might be beneficial in terms of significantly more oocytes recovered, and significantly greater number of embryos available for transfer and freezing, with no incidence of premature luteinization.
2 context sentences(design, population, supporting numbers)
Summary · context
A total of 64 normally ovulating patients entering an IVF programme were randomized to receive GnRHa (nafarelin acetate/Synarel) as an intranasal spray commencing in the midluteal phase, either at a dosage of 200 microg three times daily until the day of human chorionic gonadotrophin (HCG) administr…
Summary · context
All patients received three ampoules of Metrodin HP per day.
Report a problemFND-0980625303
04HumanRandomized controlled trialEfficacy outcome
In IVF patients, reduced-dose nafarelin yielded significantly more embryos for transfer and freezing than continued higher-dose nafarelin.
In plain wordsReduced-dose nafarelin yielded more embryos for transfer and freezing than continued higher-dose nafarelin.
Peptide
Nafarelin
Outcome
IncreaseEmbryos available for transfer and freezing
Study
n = 64
Comparator
Nafarelin 200 microg three times daily throughout stimulation
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
200 microg three times daily, reduced to 200 microg twice daily at ovarian stimulation · intranasalAs given in this study (human).
Source sentences
Summary
Our results show that reducing the GnRHa dose during ovarian stimulation in IVF might be beneficial in terms of significantly more oocytes recovered, and significantly greater number of embryos available for transfer and freezing, with no incidence of premature luteinization.
2 context sentences(design, population, supporting numbers)
Summary · context
A total of 64 normally ovulating patients entering an IVF programme were randomized to receive GnRHa (nafarelin acetate/Synarel) as an intranasal spray commencing in the midluteal phase, either at a dosage of 200 microg three times daily until the day of human chorionic gonadotrophin (HCG) administr…
Summary · context
All patients received three ampoules of Metrodin HP per day.
Report a problemFND-0980625304
05HumanNon-randomized trialSafety outcome
In IVF patients, no premature luteinization was reported with the reduced-dose nafarelin protocol.
In plain wordsNo premature luteinization was reported with reduced-dose nafarelin.
Peptide
Nafarelin
Outcome
Not applicablePremature luteinization
Study
n: not reported in source
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
200 microg three times daily, reduced to 200 microg twice daily at ovarian stimulation · intranasalAs given in this study (human).
Source sentences
Summary
Our results show that reducing the GnRHa dose during ovarian stimulation in IVF might be beneficial in terms of significantly more oocytes recovered, and significantly greater number of embryos available for transfer and freezing, with no incidence of premature luteinization.
2 context sentences(design, population, supporting numbers)
Summary · context
A total of 64 normally ovulating patients entering an IVF programme were randomized to receive GnRHa (nafarelin acetate/Synarel) as an intranasal spray commencing in the midluteal phase, either at a dosage of 200 microg three times daily until the day of human chorionic gonadotrophin (HCG) administr…
Summary · context
All patients received three ampoules of Metrodin HP per day.
Report a problemFND-0980625305

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:36 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.